Skip to main content

Pharma News

Crack GPAT — Prepare for GPAT Online 

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • HIV vaccine trial starts at Oxford

    The goal of the trial, known as HIV-CORE 0052, is to evaluate the safety, tolerability, and immunogenicity of the HIVconsvX vaccine – a mosaic vaccine targeting a broad range of HIV-1 variants, making it potentially applicable for HIV strains in any geographical region.

    Thirteen healthy, HIV-negative adults, aged 18-65 and who are considered not to be at high risk of infection, will initially receive one dose of the vaccine followed by a further booster dose at four weeks.

  • AstraZeneca receives clearance from the European Commission for the proposed acquisition of Alexion

    AstraZenecas proposed acquisition of Alexion Pharmaceuticals, Inc.has achieved an important step towards completion by having cleared the European Commission review.

    The clearance follows competition clearances in the United States, Japan and other countries globally, with a complete list available on astrazeneca.com. Regulatory clearance in the UK is pending and remains a requirement to complete the deal.

  • FDA Approves Expanded Indication for Merck KEYTRUDA in Locally Advanced Cutaneous Squamous Cell Carcinoma

    Merck known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with locally advanced cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.

  • Alvotech Initiates Clinical Studies for AVT04, a Proposed Biosimilar to Stelara

    Alvotech, the Iceland-based biosimilar company, announced that the first patient has been dosed in the comparative, confirmatory efficacy and safety clinical study (AVT04-GL-301) for AVT04, Alvotech‘s proposed biosimilar to the reference product Stelara®. The objective of the study is to demonstrate therapeutic equivalence between AVT04 and Stelara® in terms of safety, efficacy and immunogenicity in patients with moderate-to-severe chronic plaque psoriasis.

  • Connective Tissue Protein Fights Bacterial Infections While Restraining Immune Overreaction in Sepsis

    A connective tissue protein known to support the framework of organs also encourages immune responses that fight bacterial infections, while restraining responses that can be deadly in the condition called sepsis, a new study finds.

  • Two more Central Drug Laboratories at Pune and Hyderabad for Covid Vaccine Testing

    In the wake of the COVID-19 pandemic, and considering the enhanced production of COVID Vaccines, the Government proactively took the decision of setting up additional laboratories,to facilitate expedited testing / pre-release certification of the  vaccines.

  • Carbamazepine, Ranitidine and Ibuprofen cost hikes by 50 percent

    National Pharmaceutical Pricing Authority (NPPA) allows price hikes of essential medicines like Carbamazepine, Ranitidine and ibuprofen by 50 percent. They have included 9 strengths of these medicines and allows manufacturers to increase pricing after being advised by the Standing Committee on Affordable Medicines and Health Products (SCAMHP), Niti Aayog, Government of India.

  • Torrent Pharmaceutical gets exemption of DPCO for their formulation Tapentadol Nasal Spray

    National Pharmaceutical Pricing Authority (NPPA) grants exemption from Drugs Price Control Order (DPCO) 2013 to Torrent Pharmaceuticals for their formulation of Tapentadol Nasal Spray.

  • Scientists devise new strategy for combating fungal eye infection

    India has a huge agrarian population, which is very prone to vegetative trauma while farming. Vegetative trauma to the eye is generally caused by infected vegetable matter such as plant leaves and often leads to fungal infection of the cornea in the eyes or fungal keratitis.

  • Genome wide DNA methylation landscape reveals glioblastomas influence

    Caption : Expression pattern of ligands of corresponding receptors specific for CD4+ T cell lineages in GBM tumor tissue. (A-D) The heatmaps show expression of the ligands in tumor tissue and graphical representation of their corresponding receptor expression level on the CD4+ T-cells in the four major subtypes: Th1 (panel A), Th17 (panel B), Th2 (panel C) and iTreg (Panel D) CD4+ T cells in GBM tumors. Font colors (red; upregulated and blue; downregulated) of the receptors on the left to the heatmap represent expression pattern.

Subscribe to Pharma News